{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:58:14Z","timestamp":1794329894823,"version":"4.9.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Human papillomavirus (HPV) vaccination is predicted to lower the positive predictive value (PPV) of cytology.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We included 153,250 girls born between 1989 and 1993, resident in Sweden since the introduction of HPV vaccines (October 2006) and attending cervical screening at age 23 years. We assessed their first cytology and following histopathological diagnosis using Swedish National Cervical Screening Registry (NKCx). By linkage with the national Swedish HPV vaccination registry, we determined PPV of abnormal cytology for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and the differences with 95% confidence intervals (CIs) according to vaccination status.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>The PPV of high-grade cytology for CIN2+ was 69.9% (95% CI, 67.9\u201371.9), 64.9% (95% CI, 59.8\u201369.8) and 57.4% (95% CI, 50.9\u201363.7) among women unvaccinated, initiating vaccination at age 17\u201322 years and initiating vaccination before age 17 years, corresponding to reduction in PPV by 8% (95% CI, 0\u201315%) and 17% (95% CI, 7\u201326%) in vaccinated groups after adjustment for birth cohort, respectively.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The PPV of cytology for CIN2+ decreased among vaccinated women, and the decrease was stronger for girls vaccinated at younger ages. A switch from cytology to HPV testing might potentially improve the screening performance.<\/jats:p>\n<\/jats:sec>","DOI":"10.1038\/s41416-020-0850-6","type":"journal-article","created":{"date-parts":[[2020,5,3]],"date-time":"2020-05-03T23:02:38Z","timestamp":1588546958000},"page":"155-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Impact of HPV vaccination on cervical screening performance: a population-based cohort study"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-1414","authenticated-orcid":false,"given":"Jiayao","family":"Lei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Ploner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Spar\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Dillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Miriam","family":"Elfstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"850_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","volume":"189","author":"JM Walboomers","year":"1999","unstructured":"Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12\u201319 (1999).","journal-title":"J. Pathol."},{"key":"850_CR2","unstructured":"Immunization, W. Vaccines and Biologicals Database. http:\/\/www.who.int\/entity\/immunization\/monitoring_surveillance\/VaccineIntroStatus.pptx (2019). Accessed 5 December 2019."},{"key":"850_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ypmed.2018.12.014","volume":"120","author":"J Wang","year":"2019","unstructured":"Wang, J., Ploner, A., Sparen, P., Lepp, T., Roth, A., Arnheim-Dahlstrom, L. et al. Mode of HPV vaccination delivery and equity in vaccine uptake: a nationwide cohort study. Prev. Med. 120, 26\u201333 (2019).","journal-title":"Prev. Med."},{"key":"850_CR4","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1002\/ijc.30035","volume":"138","author":"E Herweijer","year":"2016","unstructured":"Herweijer, E., Sundstr\u00f6m, K., Ploner, A., Uhnoo, I., Spar\u00e9n, P. & Arnheim\u2010Dahlstr\u00f6m, L. Quadrivalent HPV vaccine effectiveness against high\u2010grade cervical lesions by age at vaccination: a population\u2010based study. Int. J. Cancer 138, 2867\u20132874 (2016).","journal-title":"Int. J. Cancer"},{"key":"850_CR5","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ijc.30721","volume":"141","author":"E Herweijer","year":"2017","unstructured":"Herweijer, E., Sundstr\u00f6m, K., Ploner, A., Uhnoo, I., Spar\u00e9n, P. & Arnheim\u2010Dahlstr\u00f6m, L. Erratum. Int. J. Cancer 141, E1\u2013E4 (2017).","journal-title":"Int. J. Cancer"},{"key":"850_CR6","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.vaccine.2018.02.097","volume":"36","author":"E Herweijer","year":"2018","unstructured":"Herweijer, E., Ploner, A. & Sparen, P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine 36, 1917\u20131920 (2018).","journal-title":"Vaccine"},{"key":"850_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30298-3","author":"M Drolet","year":"2019","unstructured":"Drolet, M., Benard, E., Perez, N. & Brisson, M., Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(19)30298-3 (2019).","journal-title":"Lancet"},{"key":"850_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1473-3099(12)70187-1","volume":"12","author":"T Malagon","year":"2012","unstructured":"Malagon, T., Drolet, M., Boily, M. C., Franco, E. L., Jit, M., Brisson, J. et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 781\u2013789 (2012).","journal-title":"Lancet Infect. Dis."},{"issue":"Suppl. 1","key":"850_CR9","doi-asserted-by":"publisher","first-page":"A46","DOI":"10.1016\/j.vaccine.2008.10.085","volume":"27","author":"P Bonanni","year":"2009","unstructured":"Bonanni, P., Boccalini, S. & Bechini, A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 27(Suppl. 1), A46\u2013A53 (2009).","journal-title":"Vaccine"},{"key":"850_CR10","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrclinonc.2013.84","volume":"10","author":"M Lehtinen","year":"2013","unstructured":"Lehtinen, M. & Dillner, J. Clinical trials of human papillomavirus vaccines and beyond. Nat. Rev. Clin. Oncol. 10, 400\u2013410 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"850_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pvr.2015.06.006","volume":"1","author":"L von Karsa","year":"2015","unstructured":"von Karsa, L., Arbyn, M., De Vuyst, H., Dillner, J., Dillner, L., Franceschi, S. et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Res. 1, 22\u201331 (2015).","journal-title":"Papillomavirus Res."},{"key":"850_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.arcmed.2009.06.003","volume":"40","author":"EL Franco","year":"2009","unstructured":"Franco, E. L., Mahmud, S. M., Tota, J., Ferenczy, A. & Coutlee, F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch. Med. Res. 40, 478\u2013485 (2009).","journal-title":"Arch. Med. Res."},{"key":"850_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson, J. F., Almqvist, C., Bonamy, A. K., Ljung, R., Michaelsson, K., Neovius, M. et al. Registers of the Swedish total population and their use in medical research. Eur. J. Epidemiol. 31, 125\u2013136 (2016).","journal-title":"Eur. J. Epidemiol."},{"key":"850_CR14","unstructured":"Swedish National Cervical Screening Registry (NKCx). Prevention of Cervical Cancer in Sweden. Annual report. http:\/\/www.nkcx.se\/templates\/_rsrapport_2018.pdf (2018). Accessed 24 Apr 2019."},{"key":"850_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","volume":"24","author":"JF Ludvigsson","year":"2009","unstructured":"Ludvigsson, J. F., Otterblad-Olausson, P., Pettersson, B. U. & Ekbom, A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur. J. Epidemiol. 24, 659\u2013667 (2009).","journal-title":"Eur. J. Epidemiol."},{"key":"850_CR16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jnci\/djt032","volume":"105","author":"A Leval","year":"2013","unstructured":"Leval, A., Herweijer, E., Ploner, A., Eloranta, S., Fridman Simard, J., Dillner, J. et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J. Natl Cancer Inst. 105, 469\u2013474 (2013).","journal-title":"J. Natl Cancer Inst."},{"key":"850_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark, B., Hammar, N., Fored, C. M., Leimanis, A., Otterblad Olausson, P., Bergman, U. et al. The new Swedish Prescribed Drug Register\u2014opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol. Drug Saf. 16, 726\u2013735 (2007).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"Suppl. 3","key":"850_CR18","first-page":"S3\/171","volume":"24","author":"EL Franco","year":"2006","unstructured":"Franco, E. L., Cuzick, J., Hildesheim, A. & de Sanjose, S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3), S3\/171\u2013S3\/17177 (2006).","journal-title":"Vaccine"},{"key":"850_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/cid\/ciw354","volume":"63","author":"SM Garland","year":"2016","unstructured":"Garland, S. M., Kjaer, S. K., Munoz, N., Block, S. L., Brown, D. R., DiNubile, M. J. et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin. Infect. Dis. 63, 519\u2013527 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"850_CR20","unstructured":"Regional Cancer Centers in Sweden in Cooperation. National Swedish Guidelines for Cervical Cancer Prevention, Diagnosis, and Treatment. https:\/\/www.cancercentrum.se\/globalassets\/vara-uppdrag\/prevention-tidig-upptackt\/gynekologisk-cellprovskontroll\/vardprogram\/nationellt-vardprogram-cervixcancerprevention.pdf (2019). Accessed 16 Jan 2020 [In Swedish]."},{"key":"850_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/bjc.2015.474","volume":"114","author":"TJ Palmer","year":"2016","unstructured":"Palmer, T. J., McFadden, M., Pollock, K. G., Kavanagh, K., Cuschieri, K., Cruickshank, M. et al. HPV immunisation and cervical screening\u2013confirmation of changed performance of cytology as a screening test in immunised women: a retrospective population-based cohort study. Br. J. Cancer 114, 582\u2013589 (2016).","journal-title":"Br. J. Cancer"},{"key":"850_CR22","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1111\/1471-0528.14563","volume":"124","author":"A Munro","year":"2017","unstructured":"Munro, A., Gillespie, C., Cotton, S., Busby-Earle, C., Kavanagh, K., Cuschieri, K. et al. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study. BJOG 124, 1394\u20131401 (2017).","journal-title":"BJOG"},{"key":"850_CR23","doi-asserted-by":"publisher","unstructured":"Sultana, F., Winch, K., Saville, M. & Brotherton, J. M. L. Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination? Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.32050 (2018).","DOI":"10.1002\/ijc.32050"},{"key":"850_CR24","doi-asserted-by":"publisher","first-page":"e007921","DOI":"10.1136\/bmjopen-2015-007921","volume":"5","author":"MS Hestbech","year":"2015","unstructured":"Hestbech, M. S., Lynge, E., Kragstrup, J., Siersma, V., Vazquez-Prada Baillet, M. & Brodersen, J. The impact of HPV vaccination on future cervical screening: a simulation study of two birth cohorts in Denmark. BMJ Open 5, e007921 (2015).","journal-title":"BMJ Open"},{"key":"850_CR25","unstructured":"Statistics for HPV vaccinations\u2014share of vaccinated girls through 2015-12-31. https:\/\/www.folkhalsomyndigheten.se\/globalassets\/statistik-uppfoljning\/vaccinationsstatistik\/hpv\/statistik-for-hpv-vaccinationer-andel-vaccinerade-flickor-tom-2015-12-31.pdf (2015). Accessed 16 Aug 2017."},{"key":"850_CR26","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","volume":"15","author":"M Drolet","year":"2015","unstructured":"Drolet, M., Benard, E., Boily, M. C., Ali, H., Baandrup, L., Bauer, H. et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect. Dis. 15, 565\u2013580 (2015).","journal-title":"Lancet Infect. Dis."},{"key":"850_CR27","doi-asserted-by":"publisher","first-page":"e1002388","DOI":"10.1371\/journal.pmed.1002388","volume":"14","author":"K Canfell","year":"2017","unstructured":"Canfell, K., Caruana, M., Gebski, V., Darlington-Brown, J., Heley, S., Brotherton, J. et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med. 14, e1002388 (2017).","journal-title":"PLoS Med."},{"key":"850_CR28","doi-asserted-by":"publisher","unstructured":"Kann, H., Hortlund, M., Eklund, C., Dillner, J. & Faust, H. Human papillomavirus types in cervical dysplasia among young HPV-vaccinated women: population-based nested case\u2013control study. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.32848 (2019).","DOI":"10.1002\/ijc.32848"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0850-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0850-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:08:20Z","timestamp":1684616900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0850-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7,7]]}},"alternative-id":["850"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0850-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"9 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Regional Ethical Review Board in Stockholm, Sweden (Dnr. 02-556; Dnr. 2011\/921-32; Dnr. 2012\/216-32 and Dnr. 2012\/1426-32), which determined that written informed consent by the study participants was not required. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Data from the study is available on request from corresponding author.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"J.D. is formerly recipient of grants on HPV vaccine research from Merck\/SPMSD, and grants to his employer (Karolinska University Hospital) from Roche and Genomica; M.L. has received grants for his HPV vaccination studies from Merck & Co., Inc. and GSK Biologicals through his employers T.H.L. and Tampere University; the other authors have no conflict of interest to declare; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was supported by CoheaHr (FP7-F3-2013-603019), Swedish Foundation for Strategic Research (KF10-0046); Swedish Cancer Society (CAN 2016\/840); Swedish Research Council (2017-02346) and the China Scholarship Council (201507930001).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}},{"value":"The study sponsor did not participate in study design, data collection, analysis, interpretation of data, writing of the article or the decision to submit it for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Role of sponsor"}}]}}